Share on StockTwits

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) has received an average rating of “Buy” from the twenty-two analysts that are currently covering the company, Analyst Ratings.Net reports. Six research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $174.05.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) opened at 136.58 on Wednesday. Jazz Pharmaceuticals plc – has a one year low of $77.25 and a one year high of $176.60. The stock’s 50-day moving average is $146.7 and its 200-day moving average is $145.3. The company has a market cap of $8.225 billion and a price-to-earnings ratio of 100.10.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter in the prior year, the company posted $1.43 earnings per share. The company’s quarterly revenue was up 39.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.18 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Thursday. They now have a $150.00 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of Jazz Pharmaceuticals plc – from $200.00 to $208.00 in a research note on Wednesday. Finally, analysts at FBR Capital Markets cut their price target on shares of Jazz Pharmaceuticals plc – from $214.00 to $213.00 in a research note on Wednesday.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.